Daptomycin is a cyclic lipopeptide antibiotic
approved by the FDA in 2003.
faecium to daptomycin, a newer cyclic lipopeptide antibiotic
that acts on the bacterial cell membrane has also been reported.
(1) Daptomycin is a cyclic lipopeptide antibiotic
derived from Streptomyces roseosporus, which shows a potent bactericidal activity against most Gram-positive organisms including MRSA.
Therefore, this first-in-class cyclic lipopeptide antibiotic
could be considered an important option for Brazilian patients.
A novel cyclic lipopeptide antibiotic
for complicated skin and skin structure infections caused by susceptible strains of these gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae sub-species equisimilis, and Enterococcus faecalis (vancomycin-susceptible strains only).